Johnson & Johnson (JNJ) announced that it has discontinued the phase II field study, which evaluated the company’s investigational antiviral candidate mosnodenvir (formerly JNJ-1802) for the prevention of dengue virus in patients aged between 18 years and 65 years.JNJ decided to stop this study (NCT05201794) as part of the strategic reprioritization of its Communicable Diseases research and development (R&D) portfolio.Year to date, shares of JNJ have risen 2.3% compared with the industry’s growth of 18.5%.I ...